Lara Albuquerque de Brito

Lara Albuquerque de Brito

Auto-generated profile, based on publicly available information

Lara Albuquerque de Brito

Hospital Geral de Fortaleza Fortaleza Ceará Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
DDDaniel Aguiar Dias
Daniel Aguiar Dias
LBLara Albuquerque de Brito
Lara Albuquerque de Brito
LNLuciana de Oliveira Neves
Luciana de Oliveira Neves
RPRoberto Guido Santos Paiva
Roberto Guido Santos Paiva
OJOctávio Alencar Barbosa Júnior
Octávio Alencar Barbosa Júnior
JTJosé Wagner Leonel Tavares-Júnior
José Wagner Leonel Tavares-Júnior
Critically-ill patients with COVID-19 have an extreme inflammatory reaction, causing a cytokine storm syndrome that may damage the blood-brain barrier and complicate with PRES1. The associated hemorrhage seen in our patients may also be explained by coagulation impairment, another common complication reported in COVID-19 patients2.

28 August 2026 in Journal of the Peripheral Nervous System
Verified
Journal Article
Open access
APAnna Paula Paranhos
Anna Paula Paranhos
MCMarcela Câmara Machado Costa
Marcela Câmara Machado Costa
CMCarolina Lavigne Moreira
Carolina Lavigne Moreira
DSDiogo Fernandes dos Santos
Diogo Fernandes dos Santos
MFMarcondes C. França
Marcondes C. França
WMWilson Marques
Wilson Marques
Background and Aims: The Val122Ile ATTR Amyloidosis has traditionally been linked to cardiac manifestations. Recent studies suggest that neuropathy may be relevant. In this study, we characterized its peripheral nerve manifestations in depth. Methods: This was a national, multicenter, observational, retrospective study. Patients underwent careful clinical and neurophysiological evaluation. We excluded those with alternative etiologies. Results: We identified 246 Val122Ile carriers, including 240 heterozygous, 4 homozygous, and 2 compound heterozygous. Gender distribution was similar. Age of onset: 19–89 years, mean 53 ± 17. Self‐reported ethnicity: White (26.7%), Black (17.3%), and Mixed (Pardo) (56.0%). Birthplaces spanned all Brazilian regions, mainly the Northeast. Among heterozygotes, 52 of 122 (42.6%) were symptomatic. Carpal tunnel syndrome (CTS) preceded polyneuropathy and/or cardiomyopathy in 69.2%. The most frequent onset manifestations, excluding CTS, were cardiomyopathy (52.9%), neuropathy (37.3%), and mixed phenotype (9.8%). Age of onset: 29–86 years (mean: 64.9 years). During follow‐up, 14/27 cardiac patients developed neuropathy, and 8/19 neurologic patients developed cardiomyopathy, significantly increasing the mixed phenotype from 9.8% to 52.9%. Most patients with neuropathy presented with sensory or sensory and motor disease (62.2%), followed by small fiber neuropathy (32.4%), and isolated dysautonomia (5.4%). Interpretation: Neuropathy is underrecognized in Val122Ile ATTR Amyloidosis, is frequent at disease onset, may be the sole manifestation, and may occur in White persons. CTS frequently preceded neuropathy, usually an axonal polyneuropathy, although atypical patterns were observed. This variant clusters in the Northeast region of Brazil.

18 December 2025 in Amyloid
Verified
Journal Article
Closed access
LBLara Albuquerque de Brito
Lara Albuquerque de Brito
CRCleonisio Leite Rodrigues
Cleonisio Leite Rodrigues
ALAlexandre Liborio
Alexandre Liborio
RLRaynrich Kevin Assis Lima
Raynrich Kevin Assis Lima
HFHermany Capistrano Freitas
Hermany Capistrano Freitas
FCFernanda Martins Maia Carvalho
Fernanda Martins Maia Carvalho

12 May 2026 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
JBJosé Pedro Soares Baima
José Pedro Soares Baima
CDCaio César Diniz Disserol
Caio César Diniz Disserol
EOEduardo Braga de Oliveira
Eduardo Braga de Oliveira
NANatália Merten Athayde
Natália Merten Athayde
LBLara Albuquerque de Brito
Lara Albuquerque de Brito
CRCleonisio Leite Rodrigues
Cleonisio Leite Rodrigues
Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.